CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 360.81M |
| Revenue (ttm) | 66.74M |
| Net Income (ttm) | -60.64M |
| Shares Out | 60.97M |
| EPS (ttm) | -1.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $5.55 |
| Previous Close | $5.63 |
| Change ($) | -0.08 |
| Change (%) | -1.42% |
| Day's Open | 5.69 |
| Day's Range | 5.52 - 5.74 |
| Day's Volume | 462,382 |
| 52-Week Range | 5.52 - 10.05 |
CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat...
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 10.34% and -21.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat...
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investig...
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investi...
With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of...
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investi...
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
-Broad advancement of clinical pipeline-
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investig...
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (NASDAQ:CTMX).
All four biotechs announced the pricing of stock offerings.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives w...
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...
While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investiga...
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2020 Results - Earnings Call Transcript
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 11.11% and 1.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT- -Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT-
Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi...
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of invest...
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi...
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 20, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. between May 17, 2018, and May 13, 2020, inclu...
New York, New York--(Newsfile Corp. - July 20, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc.
Los Angeles, California--(Newsfile Corp. - July 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
New York, New York--(Newsfile Corp. - July 17, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc.
Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...
New York, New York--(Newsfile Corp. - July 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc.
New York, New York--(Newsfile Corp. - July 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cyto...
Los Angeles, California--(Newsfile Corp. - July 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...
Los Angeles, California--(Newsfile Corp. - July 15, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc. ("CytomX" or "the Company") (Nasdaq: CTMX) an...
Los Angeles, California--(Newsfile Corp. - July 14, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...
Los Angeles, California--(Newsfile Corp. - July 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics...
NEW YORK, July 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May ...
NEW YORK, July 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May 1...
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gas... [Read more...]
| Industry Biotechnology | IPO Date Oct 8, 2015 |
| CEO Sean McCarthy | Employees 144 |
| Stock Exchange NASDAQ | Ticker Symbol CTMX |
Financial Performance
In 2020, CTMX's revenue was $100.36 million, an increase of 74.58% compared to the previous year's $57.49 million. Losses were -$32.89 million, -67.83% less than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is 12.94, which is an increase of 133.15% from the latest price.